Loading organizations...
§ Private Profile · Wuxi Shi, Jiangsu, China
Biotechnology company developing precision therapies for oncology and immunology, addressing unmet patient needs with biomarker strategies.
D3 Bio is a Wuxi, China-based biotechnology company that develops precision medicines and therapies focused on oncology and immunology. The clinical-stage enterprise utilizes clinical insights and biomarker strategies to guide its internal research and development pipeline, aiming to address unmet patient needs across multiple indications. To support its clinical programs and independent pipeline development, the company has secured a total of $240 million in venture capital funding. This financial backing includes a $200 million Series A round and a recent $40 million financing, drawing investments from prominent firms such as Sequoia Capital China, Temasek, Boyu Capital, and Matrix Partners China. The organization recently expanded its leadership by appointing pharmaceutical veteran Antoine Yver as an independent board member to help guide its future strategic growth. D3 Bio was officially founded in 2020 by George Chen.
D3 Bio has raised $370.0M across 3 funding rounds.
D3 Bio has raised $370.0M in total across 3 funding rounds.
D3 Bio has raised $370.0M across 3 funding rounds. Most recently, it raised $108.0M Series B in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 10, 2025 | $108M Series B | — | IDG Capital, Matrix Partners China, Medicxi, Sequoia Capital, Temasek, WuXi AppTec | Announced |
| Apr 8, 2024 | $62M Series A | Francesco DE Rubertis | Matrix Partners China, WuXi AppTec | Announced |
| Nov 17, 2020 | $200M Series A | — | Yanling CAO, Hongshan Capital Group (Sequoia Capital China), Matrix Partners China, Temasek, WuXi AppTec | Announced |
D3 Bio has raised $370.0M in total across 3 funding rounds.
D3 Bio's investors include IDG Capital, Matrix Partners China, Medicxi, Sequoia Capital, Temasek, WuXi AppTec, Francesco De Rubertis, Yanling Cao, Hongshan Capital Group (Sequoia Capital China).